These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21923319)

  • 1. Should the DEA conduct a "patient impact assessment" when promulgating new restrictions on controlled substance distribution?
    Brushwood DB
    J Pain Palliat Care Pharmacother; 2008; 22(4):322-6. PubMed ID: 21923319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Issuance of multiple prescriptions for schedule II controlled substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2007 Nov; 72(222):64921-30. PubMed ID: 18038486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The federal Drug Enforcement Administration "prescription series" proposal: continuing concerns.
    Gilson AM; Joranson DE
    J Pain Palliat Care Pharmacother; 2007; 21(4):21-4. PubMed ID: 18032312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes to patient limitation for dispensing or prescribing approved narcotic controlled substances for maintenance or detoxification treatment by qualified individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2008 May; 73(100):29685-8. PubMed ID: 18605404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DEA issues proposed rule on e-prescribing.
    Ball FR
    J Med Pract Manage; 2009; 24(4):243. PubMed ID: 19288650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Drug Enforcement Administration guideline for communicating controlled substance prescriptions to pharmacies.
    Drug Enforcement Adminstration U S Department of Justice
    J Pain Palliat Care Pharmacother; 2011; 25(1):83-9. PubMed ID: 21426229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescriptions; dispensing controlled substances in institutional practitioner emergency rooms--Drug Enforcement Administration, Justice. Withdrawal of proposed rule.
    Fed Regist; 1983 Jun; 48(125):29713-4. PubMed ID: 10261481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DEA issues new clarification regarding prescribing schedule II controlled substances.
    Heitz R
    WMJ; 2005 Apr; 104(3):55. PubMed ID: 15966635
    [No Abstract]   [Full Text] [Related]  

  • 9. Dear DEA.
    Heit HA; Covington E; Good PM
    Pain Med; 2004 Sep; 5(3):303-8. PubMed ID: 15367311
    [No Abstract]   [Full Text] [Related]  

  • 10. Prescriptions for Schedule II controlled substances: Drug Enforcement Administration, Justice. Notice of proposed rulemaking.
    Fed Regist; 1980 Apr; 45(70):24199-200. PubMed ID: 10246081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Registration and reregistration application fees. Confirmation of final rule, remanded for further notice and comment, and response to comments.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2002 Aug; 67(154):51987-52007. PubMed ID: 12194173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dispensing controlled substances in institutional practitioner emergency rooms--Drug Enforcement Administration. Notice of proposed rulemaking.
    Fed Regist; 1982 Sep; 47(181):41140. PubMed ID: 10262071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescriptions; requirements clarification--Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1991 Jun; 56(106):25025-7. PubMed ID: 10111144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allowing central fill pharmacies and retail pharmacies to fill prescriptions for controlled substances on behalf of retail pharmacies. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 Jun; 68(121):37405-11. PubMed ID: 12836645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Registration and reregistration application fees. Final rule; remanded for further notice and comment.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 1996 Dec; 61(251):68624-6. PubMed ID: 12192680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled substances in long-term care pharmacy: part 2.
    Martin CM
    Consult Pharm; 2008 Oct; 23(10):742-56. PubMed ID: 19032014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Drug Enforcement Agency and DEA Form 104.
    Stratton WT
    Kans Med; 1994 Oct; 95(10):212, 214. PubMed ID: 7815771
    [No Abstract]   [Full Text] [Related]  

  • 18. The regulatory process: impacting the NP's role.
    Wysocki S
    Nurse Pract Forum; 1992 Jun; 3(2):56-7. PubMed ID: 1392671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doctors with multi-state practices beware: new DEA regulation could affect you.
    Ball FR
    J Med Pract Manage; 2007; 23(2):104-5. PubMed ID: 17974088
    [No Abstract]   [Full Text] [Related]  

  • 20. Exempt chemical mixtures containing gamma-butyrolactone. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Jun; 75(124):37301-7. PubMed ID: 20608286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.